chevron_leftBack
As of 14 June 2026, Ocumension Therapeutics has a market cap of $780.3M USD, ranking #12197 globally and #3607 in China.
It ranks #2733 in the Industrials sector, and #250 in the Specialty Business Services industry.
Key Stats
Market Cap
$780.3MUSD
6.12B HKD
Enterprise Value
$749.89MUSD
5.88B HKD
Revenue (TTM)
$114.21MUSD
895.09M HKD
EBITDA (TTM)
-$11.81MUSD
-92.52M HKD
Net Income (TTM)
-$22.55MUSD
-176.74M HKD
EBITDA Margin
-10%
Profit Margin
-20%
Forward PE
163.6
PS Ratio
6.8
PB Ratio
1.5
Company Profile
Country (HQ)
Sector
Industrials
Industry
Specialty Business Services
CEO
Ye Liu
open_in_new
Employees
552
Founded
2017
Website
ocumension.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.3% | -3.5% | 2.3% | 4.6% | -7.3% | 38% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
1477
歐康維視生物 Ordinary Shares
ISIN: KYG674111011
Shares Out.:
Shares Outstanding:
823.014M1
Shares Float:
345.518M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
7.40 HKD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Ocumension Therapeutics
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. The company was founded in 2017 and is based in Suzhou, the People's Republic of China.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SHEK: 2268
|
$9.42B
1K%
73.79B HKD
|
47.0
|
|
SHE: 300803
|
$8.76B
1K%
59.36B CNY
|
296.1
|
|
NYSE: TAL
|
$6.6B
746%
|
11.8
|
|
SHE: 001267
|
$6.25B
701%
42.34B CNY
|
480.6
|
|
SSE: 605376
|
$4.62B
492%
31.29B CNY
|
128.4
|
|
SHE: 301626
|
$4.6B
489%
31.16B CNY
|
163.3
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: SHOP
|
$158.14B
20K%
|
129.8
|
|
STO: VSURE
|
$132.68B
17K%
114.8B EUR
|
-
|
|
NASDAQ: CTAS
|
$69.6B
9K%
|
36.8
|
|
LSE: REL
|
$63.78B
8K%
47.6B GBP
|
23.9
|
|
NASDAQ: PYPL
|
$45.83B
6K%
|
9.4
|
|
|
T
NEO: TRI
|
$41.8B
5K%
56.91B CAD
|
-
|
chevron_leftBack